Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 8/20 | 0.48 |
| ▸ | F2 | P00734 | 13/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 12/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 12/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 12/20 | 0.47 |
| ▸ | PLG | P00747 | 2/20 | 0.46 |
| ▸ | PLAT | P00750 | 2/20 | 0.46 |
| ▸ | F7 | P08709 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7073613 | 0.90 | F10 (0.59) | LTB4R2F10F2PRSS1PRSS2 | |
| SCHEMBL7075440 | 0.89 | F10 (0.52) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7070282 | 0.88 | F10 (0.46) | LTB4R2F10F2PRSS1PRSS2 | |
| SCHEMBL7073588 | 0.87 | F10 (0.49) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7099089 | 0.87 | F10 (0.50) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7068387 | 0.86 | F2 (0.49) | LTB4R2F10F2PRSS1PRSS2 | |
| SCHEMBL7076082 | 0.86 | F10 (0.50) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7073651 | 0.86 | F10 (0.48) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7069957 | 0.85 | F2 (0.43) | LTB4R2F10F2PRSS1PRSS2 | |
| SCHEMBL7074934 | 0.84 | LTB4R2 (0.52) | LTB4R2F10F2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187037-A1 | Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia | MERCK-PATENT GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187037-A1 | Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia | F12, F11, PLAT | LTB4R2 690/4885F10 17/4885F2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.